عرض بسيط للتسجيلة

المؤلفChowdhury, Shazeda
المؤلفTaleb, Sara
المؤلفElgamal, Mahmoud
المؤلفHassan, Nesyia
المؤلفNomikos, Michail
المؤلفHssain, Ali Ait
المؤلفZughaier, Susu M
تاريخ الإتاحة2022-03-24T05:33:59Z
تاريخ النشر2021
اسم المنشورJournal of Emergency Medicine, Trauma and Acute Care
المصدرqscience
الاقتباسChowdhury S, Taleb S, Elgamal M, Hassan N, Nomikos M, Hssain AA, Zughaier SM. Development of an in-house COVID-19 serology ELISA Test, Journal of Emergency Medicine, Trauma & Acute Care, Qatar Health Care Conference 2021:7 http://dx.doi.org/10.5339/-jemtac.2021.qhc.7
الرقم المعياري الدولي للكتاب1999-7094
معرّف المصادر الموحدhttps://doi.org/10.5339/jemtac.2021.qhc.7
معرّف المصادر الموحدhttp://hdl.handle.net/10576/28965
الملخصBackground: COVID-19 pandemic created an unprecedented demand for reagents and diagnostic tools to confirm COVID-19 cases. Thus, the development of a robust in-house diagnostic test is considered of high importance. Within a few days after exposure, the human body produces specific antibodies that recognize the surface proteins of the invading SARS-CoV-2 virus 1 . Therefore, virus specific immunoglobulins are neutralizing antibodies and their appearance in the blood is a good sign of immunity 2 . The aim of this study was to develop an in-house COVID-19 serology ELISA test to quantify induced antibody responses. This test can help identify convalescent plasma donors with high antibody titers that can be used to treat other patients. Methods: Spike protein antigen is highly expressed in SARS-CoV-2 3 . Recombinant protein corresponding to the spike receptor-binding domain (RBD), which binds to specific antibodies circulating in COVID-19 patients' blood was used as the antigen in this colorimetric ELISA test. Briefly, a 96-microtiter well plate was coated with RBD protein, where serum dilutions were added. Antibody titers were detected using an anti-human IgG- peroxidase labelled antibody and the substrate o-phenylenediamine dihydrochloride; measured at optical density (OD) of 450 nm (Figure 1). Results: The in-house quantitative serology test was validated using serum samples collected from severe COVID-19 patients (n = 282) admitted to the intensive care unit at Hamad General Hospital. Serum samples from non-COVID-19 (n = 10) were used as a negative control. We detected high antibody titers in ~90% of COVID-19 sera. In contrast, no SARS-CoV-2 specific antibodies were detected in the serum of non-infected subjects (n = 6), pooled human serum collected before 2019, or Middle East Respiratory Syndrome (MERS) infected subjects (n = 3) confirming the specificity and the sensitivity of this in-house serology test. Conclusion: This in-house quantitative serology test is sensitive, specific, and inexpensive. The test can address the rising issue of COVID-19 supply chain globally and foster the capacity-building efforts envisioned by Qatar University.
اللغةen
الناشرHamad bin Khalifa University Press (HBKU Press)
الموضوعCOVID-19
SARS-CoV2
serology
antibody titer
ELISA
العنوانDevelopment of an in-house COVID-19 serology ELISA Test
النوعArticle
رقم العدد2
رقم المجلد2021
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة